Risedronate for the Prevention of Osteoporosis in People With Spinal Cord Injury.

• Status: Completed
• Trial end date: 2005-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to find out if Risedronate works to prevent osteoporosis after spinal cord injury.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Toronto Rehabilitation Institute
• Collaborators: Ontario Neurotrauma Foundation; Queen Elizabeth Hospital NHS Foundation Trust; St. Joseph's Healthcare Foundation
• Treatments: Etidronic Acid; Risedronate Sodium; Risedronic Acid

Criteria

Inclusion Criteria:

• Traumatic spinal cord injury less than 100 days.

• Must be able to swallow tablets and sit upright.

Exclusion Criteria:

• Bilateral knee flexion contractures.

• Pregnant, lactating or post-menopausal females.

• Paget's disease, osteomalacia, steroid induced bone loss, untreated thyroid disease, iritis, uveitis, pancreatitis, gastritis, peptic ulcer or cholecystitis.

• Treatment in the last year with calcitonin, fluoride or anabolic steroid.

• Concurrent treatment with prednisone.